Home » Topics » BioWorld Science

BioWorld Science
RSS

Beijing Scitech-Mq Pharmaceuticals describes RET and VEGFR2 inhibitors

Sep. 4, 2019

Jiangsu Aosaikang Pharmaceutical identifies H+/K+ ATPase inhibitors

Sep. 4, 2019

Phase II trial of AR-105 for ventilator-associated pneumonia does not meet primary endpoint

Sep. 4, 2019

Medshine Discovery divulges kynurenine production inhibitors

Sep. 4, 2019

Turning Point Therapeutics reports new data on repotrectinib and TPX-0046

Sep. 4, 2019

Positive preclinical data presented for Cocrystal Pharma's CC-42344

Sep. 4, 2019

Pfizer synthesizes new KRAS inhibitors

Sep. 4, 2019

Phase III AMPLIFY study of phosphate absorption inhibitor tenapanor meets primary endpoint

Sep. 4, 2019

Discovery of a first-in-class dual adenosine A2A/A2B receptor antagonist

Sep. 4, 2019

Machine learning from adversity speeds compound development

Sep. 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...